– Interview with Eric Schadt, Ph.D., Executive Scientific Director of Research Genetics for Rosetta Inpharmatics, Inc., a wholly-owned subsidiary of Merck & Co.

Previous articleLilly Beefs Up Biomarker Analysis Deal with HistoRx
Next articlePharmAthene Retains GTC’s Manufacturing Services for Protexia